Skip to main content

Table 2 Cross-sectional associations between serum TNC levels and clinical and laboratory parameters of patients with SLE at the inception visit (univariate and age- and sex-adjusted regression analyses)

From: Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study

  Univariate analyses Age– and sex–adjusted analyses
Variable β valueb (95 % CI) p Value β valueb (95 % CI) p Value
Patients with SLE vs. HC 46 (−17 to 110) 0.151 44 (−24 to 112) 0.205
Patients with SLE with SLEDAI-2 K ≥6 vs. HC 147 (50–245) 0.004 139 (34– 245) 0.010
Patients with SLE with SLEDAI-2 K ≥6 vs. SLEDAI-2 K <6 153 (50–256) 0.004 161 (54–267) 0.004
Patients with SLE (categorical variables)
 Any SLEDAI-2 K clinical features (yes vs. no) 107.8 (8.1–207.4) 0.035 108.4 (3.6–213.3) 0.043
 Neuropsychiatric clinical featuresa (yes vs. no) −211.9 (−488.9 to 65.2) 0.131 −202.5 (−485.8 to 80.8) 0.158
 Vasculitisa (yes vs. no)
 Arthritisa (yes vs. no) 48.3 (−87.7 to 184.2) 0.480 46.0 (−94.4 to 186.4) 0.514
 Myositisa (yes vs. no)
 Renal featuresa (yes vs. no) 265.2 (133.5–396.9) <0.001 269.7 (135.9–403.5) <0.001
 Rasha (yes vs. no) −2.1 (−144.6 to 140.4) 0.977 −9.1 (−154.9 to 136.6) 0.901
 Alopeciaa (yes vs. no) −84.6 (−267.0 to 97.8) 0.357 −85.0 (−270.7 to 100.7) 0.363
 Mucosal ulcersa (yes vs. no)
 Serositisa (yes vs. no) 231.1 (−160.4 to 622.6) 0.242 216.6 (−187.5 to 620.7) 0.287
 Haematological featuresa (yes vs. no) 20.4 (−212.5 to 253.3) 0.861 9.1 (−231.3 to 249.5) 0.940
 Fevera (yes vs. no)
 Anti-dsDNA antibodies IF (positive vs. negative) 115 (12–218) 0.029 112 (3–221) 0.044
 Complement C3/C4 (low vs. normal) −4 (−107 to 99) 0.938 −14 (−123 to 94) 0.793
 Anti-nucleosome antibodies (positive vs. negative) 138 (38–238) 0.008 131 (30–234) 0.013
Patients with SLE (continuous variables)
 SLEDAI-2 K 14 (−1 to 29) 0.061 14 (−1.5 to 30) 0.074
 cSLEDAI-2 K (only clinical SLEDAI-2 K items) 16 (−1 to 33) 0.060 16 (−1.0 to 34) 0.065
 C3, g/L −9 (−209 to 192) 0.931 5 (−205 to 216) 0.958
 C4, g/L −232 (−695 to 230) 0.319 −210 (−694 to 273) 0.386
 Anti-nucleosome antibodies, U −0.2 (−0.7 to 0.3) 0.403 −0.2 (−0.7 to 0.3) 0.460
 Anti-dsDNA antibodies, titre 27 (−22 to 75) 0.266 30 (−21 to 81) 0.230
 Urinary protein/creatinine ratio, mg/mmol 270 (101–439) 0.002 271 (98–444) 0.003
  1. CI confidence interval, HC healthy controls, IF immunofluorescence, anti-dsDNA anti–double-stranded DNA, SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000
  2. aAccording to SLEDAI-2 K definitions; renal, haematological, serositis and neuropsychiatric SLEDAI-2 K features were merged into one item (see Definitions section of text)
  3. bThe regression coefficient β corresponds to the difference in TNC levels between groups (when assessing categorical variables) or to the change in TNC associated with a 1 unit increase in the assessed variable (when assessing continuous variables)
  4. Boldface type indicates statistically significant values